-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Beclomethasone Dipropionate in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Beclomethasone Dipropionate in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Beclomethasone Dipropionate in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Company Profile
Soligenix Inc – Company Profile
Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development and commercialization of products for the treatment of rare diseases and unmet medical needs. It develops specialized biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn's disease, oral mucositis, mild to moderate psoriasis, and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation. The company has active...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – beclomethasone dipropionate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry beclomethasone dipropionate Drug Details SGX-203 (beclomethasone 17,21-dipropionate or BDP) is under development for the...